| ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms. | ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms.
Shi Z, Liu J, Zhao Y, Yang L, Cai Y, Zhang P, Xu Z, Qin T, Qu S, Pan L, Wu J, Yan X, Li Z, Zhang W, Yan Y, Huang H, Huang G, Li B, Wu X, Xiao Z., Free PMC Article | 05/5/2023 |
| Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors. | Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
Braun TP, Estabrook J, Schonrock Z, Curtiss BM, Darmusey L, Macaraeg J, Enright T, Coblentz C, Callahan R, Yashar W, Taherinasab A, Mohammed H, Coleman DJ, Druker BJ, Demir E, Lusardi TA, Maxson JE., Free PMC Article | 02/15/2023 |
| ASXL1/2 mutations and myeloid malignancies. | ASXL1/2 mutations and myeloid malignancies.
Medina EA, Delma CR, Yang FC., Free PMC Article | 09/17/2022 |
| CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression. | CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression.
Liu X, Sato N, Shimosato Y, Wang TW, Denda T, Chang YH, Yabushita T, Fujino T, Asada S, Tanaka Y, Fukuyama T, Enomoto Y, Ota Y, Sakamoto T, Kitamura T, Goyama S., Free PMC Article | 04/30/2022 |
| Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. | Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J., Free PMC Article | 03/5/2022 |
| A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. | A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells.
Yamamoto K, Goyama S, Asada S, Fujino T, Yonezawa T, Sato N, Takeda R, Tsuchiya A, Fukuyama T, Tanaka Y, Yokoyama A, Toya H, Kon A, Nannya Y, Onoguchi-Mizutani R, Nakagawa S, Hirose T, Ogawa S, Akimitsu N, Kitamura T. | 02/12/2022 |
| BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion. | BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
Perez-Garcia V, Lea G, Lopez-Jimenez P, Okkenhaug H, Burton GJ, Moffett A, Turco MY, Hemberger M., Free PMC Article | 09/25/2021 |
| The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia. | The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
D'Altri T, Wilhelmson AS, Schuster MB, Wenzel A, Kalvisa A, Pundhir S, Meldgaard Hansen A, Porse BT., Free PMC Article | 07/10/2021 |
| Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. | Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, Matsumoto A, Yamaguchi K, Isobe Y, Tsuchiya A, Shikata S, Sato N, Morinaga H, Fukuyama T, Tanaka Y, Fukushima T, Takeda R, Yamamoto K, Honda H, Nishimura EK, Furukawa Y, Shibata T, Abdel-Wahab O, Suematsu M, Kitamura T., Free PMC Article | 04/17/2021 |
| Asxl1 exerts an antiproliferative effect on mouse lung maturation via epigenetic repression of the E2f1-Nmyc axis. | Asxl1 exerts an antiproliferative effect on mouse lung maturation via epigenetic repression of the E2f1-Nmyc axis.
Moon S, Im SK, Kim N, Youn H, Park UH, Kim JY, Kim AR, An SJ, Kim JH, Sun W, Hwang JT, Kim EJ, Um SJ., Free PMC Article | 12/14/2019 |
| Asxl1 played a critical role in regulating genes associated with neural differentiation without affecting self-renewal of mouse embryonic stem cells. | Asxl1 ablation in mouse embryonic stem cells impairs neural differentiation without affecting self-renewal.
An S, Park UH, Moon S, Kang M, Youn H, Hwang JT, Kim EJ, Um SJ. | 09/21/2019 |
| Concomitant mutations of ASXL1 and RAS pathway genes were associated with aggressive progression of myeloid malignancies | Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
Zhang P, He F, Bai J, Yamamoto S, Chen S, Zhang L, Sheng M, Zhang L, Guo Y, Man N, Yang H, Wang S, Cheng T, Nimer SD, Zhou Y, Xu M, Wang QF, Yang FC., Free PMC Article | 09/21/2019 |
| the osteoclastogenesis of ASXL1 deficiency does not involve classical RANKL- or M-CSF-stimulated molecules such as MAPKs and c-Fos but activation of NFATC1 by reversal of suppressive histone methylation. | ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.
Rohatgi N, Zou W, Collins PL, Brestoff JR, Chen TH, Abu-Amer Y, Teitelbaum SL., Free PMC Article | 08/31/2019 |
| These findings reveal that ASXL1 mutations confer hematopoietic stem cells with an altered epigenome and increase susceptibility for leukemic transformation. | Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R, Inoue D, Pastore A, Fujino T, Hou HA, Yamasaki N, Goyama S, Saika M, Kanai A, Sera Y, Horikawa S, Ota Y, Asada S, Hayashi Y, Kawabata KC, Takeda R, Tien HF, Honda H, Abdel-Wahab O, Kitamura T., Free PMC Article | 06/22/2019 |
| ASXL1 mutation is associated with hematological disorders caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification. | Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
Uni M, Masamoto Y, Sato T, Kamikubo Y, Arai S, Hara E, Kurokawa M. | 06/1/2019 |
| ASXL1 truncation is associated with myeloid malignancy. | Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, Harbour JW, Xu M, Yang FC., Free PMC Article | 05/25/2019 |
| ASXL1(aa1-587) plays a gain-of-function role in promoting myeloid malignancies. | Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, Harbour JW, Wahlestedt C, Xu M, Yang FC., Free PMC Article | 04/20/2019 |
| Asxl1 deficiency leads to growth retardation. | Asxl1 deficiency in embryonic fibroblasts leads to cellular senescence via impairment of the AKT-E2F pathway and Ezh2 inactivation.
Youn HS, Kim TY, Park UH, Moon ST, An SJ, Lee YK, Hwang JT, Kim EJ, Um SJ., Free PMC Article | 02/9/2019 |
| Mutant ASXL1 cooperates with BAP1 to promote myeloid leukemogenesis. | Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S, Goyama S, Inoue D, Shikata S, Takeda R, Fukushima T, Yonezawa T, Fujino T, Hayashi Y, Kawabata KC, Fukuyama T, Tanaka Y, Yokoyama A, Yamazaki S, Kozuka-Hata H, Oyama M, Kojima S, Kawazu M, Mano H, Kitamura T., Free PMC Article | 12/22/2018 |
| study underscores the ASXL1-cohesin interaction as a novel means to maintain normal sister chromatid separation and regulate gene expression in hematopoietic cells. | ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis.
Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J, Chen S, Yang H, He Y, Li J, Guo Y, Zhang W, Hajiramezanali E, An H, Fajardo D, Harbour JW, Ruan Y, Nimer SD, Yu P, Chen X, Xu M, Yang FC., Free PMC Article | 10/13/2018 |
| This study proposed the first Asxl1 mutation knock-in mouse model and showed mutated Asxl1 lowered the threshold of MN1-driven engraftment and exhibited distinct biological functions on physiological and malignant hematopoiesis, although it was insufficient to lead to blood malignancies. | The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
Hsu YC, Chiu YC, Lin CC, Kuo YY, Hou HA, Tzeng YS, Kao CJ, Chuang PH, Tseng MH, Hsiao TH, Chou WC, Tien HF., Free PMC Article | 01/6/2018 |
| Loss of Asxl1 alters self-renewal and cell fate of bone marrow stromal cell, leading to Bohring-Opitz-like syndrome in mice. | Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.
Zhang P, Xing C, Rhodes SD, He Y, Deng K, Li Z, He F, Zhu C, Nguyen L, Zhou Y, Chen S, Mohammad KS, Guise TA, Abdel-Wahab O, Xu M, Wang QF, Yang FC., Free PMC Article | 11/18/2017 |
| implicate Asxl1 in the maintenance of podocyte structure via its association with Wtip and in the regulation of WT1 signaling during early kidney development | Role of Asxl1 in kidney podocyte development via its interaction with Wtip.
Moon S, Um SJ, Kim EJ. | 04/23/2016 |
| ASXL1 truncation mutations confer gain-of-function on the ASXL-BAP1 complex. | Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, Lähdesmäki H, Rao A., Free PMC Article | 04/9/2016 |
| Asxl1-/- fetuses have reduced body weight and display cleft palate, anophthalmia as well as ventricular septal defects and a failure in lung maturation. | Additional sex combs-like family genes are required for normal cardiovascular development.
McGinley AL, Li Y, Deliu Z, Wang QT. | 02/21/2015 |